Scarica l'app Stockscreener
0.463
3.23%
0.0145
Precedente Chiudi:
$0.4485
Aprire:
$0.435
Volume 24 ore:
748.13K
Relative Volume:
1.49
Capitalizzazione di mercato:
$8.74M
Reddito:
-
Utile/perdita netta:
$-16.26M
Rapporto P/E:
-0.3919
EPS:
-1.1814
Flusso di cassa netto:
$-13.50M
1 W Prestazione:
-2.57%
1M Prestazione:
-17.31%
6M Prestazione:
-83.16%
1 anno Prestazione:
-90.70%
Intervallo 1D:
$0.4217
$0.58
Intervallo di 1 settimana:
$0.4217
$0.63
Portata 52W:
$0.29
$5.10
Intensity Therapeutics Inc Stock (INTS) Company Profile
Nome
Intensity Therapeutics Inc
Settore
Industria
Telefono
203-221-7381
Indirizzo
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Confronta INTS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
0.463 | 8.74M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Intensity Therapeutics Inc Borsa (INTS) Ultime notizie
Intensity Therapeutics Faces Nasdaq Delisting Notice - TipRanks
Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference - The Globe and Mail
Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews
Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - Morningstar
Intratumoral Cancer Treatment Market 2034: EMA, PDMA, FDA - openPR.com
Intensity Therapeutics to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy - marketscreener.com
Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon - Morningstar
Liposarcoma Clinical Trial Analysis: Key Insights into Rich - GlobeNewswire
Imunon Stock Price, Quotes and Forecasts | NASDAQ:IMNN - Benzinga
Intensity Therapeutics stock hits 52-week low at $0.29 By Investing.com - Investing.com Nigeria
Intensity Therapeutics stock hits 52-week low at $0.29 - Investing.com
Alliance Global Partners Adjusts Price Target for Intensity Therapeutics (INTS) | INTS Stock News - GuruFocus
Benchmark maintains Speculative Buy on Intensity Therapeutics stock - Investing.com
Benchmark maintains Speculative Buy on Intensity Therapeutics stock By Investing.com - Investing.com India
Intensity Therapeutics Faces Nasdaq Non-Compliance Notice - TipRanks
Soft Tissue Sarcoma Pipeline Appears Robust With 70+ Key Pharma - openPR.com
Soft Tissue Sarcoma Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Intra-tumoral Cancer Therapies Market to Show Tremendous Growth at a CAGR of 31.3% During the Study Period (2020-2034) | DelveInsight - Yahoo Finance
Intensity stock rating cut to Hold by Brookline Capital - Investing.com Nigeria
Intensity Therapeutics (INTS) Downgraded as Funding Concerns Ari - GuruFocus
Brookline Capital Downgrades Intensity Therapeutics to Hold From Buy - marketscreener.com
Intensity Therapeutics (INTS) Downgraded as Funding Concerns Arise | INTS Stock News - GuruFocus
Intensity Therapeutics downgraded to Hold from Buy at Brookline - TipRanks
Intensity Therapeutics Reports Q1 2025 Financial Results - TipRanks
Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), Nkarta (NKTX) and Kamada (KMDA) - The Globe and Mail
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Me - Quantisnow
INTS Faces Challenges Yet Advances in Key Cancer Programs | INTS Stock News - GuruFocus
Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - Nasdaq
Health Beat: Muscle loss and cognitive function - WFMZ.com
International Hummus Day arrives with a surge in plant-based picks - WFMZ.com
Curious? Healthy Brain Aging Might Depend On It - WFMZ.com
Oropharyngeal Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight - Barchart.com
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Reg - GuruFocus
Intensity Therapeutics (INTS) Expands Cancer Trial to France | I - GuruFocus
Intensity Therapeutics (INTS) Expands Cancer Trial to France | INTS Stock News - GuruFocus
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast - Yahoo Finance
Cholangiocarcinoma Clinical Trials and Studies 2025: EMA, - openPR.com
Cholangiocarcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - Barchart.com
Offerings News Live Feed - Stock Titan
Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds - Barchart.com
Intratumoral Cancer Therapies Market Predicted to See Upsurge - openPR.com
Post-Trade Analysis: Intensity Therapeutics Inc (INTS) Climbs 12.57, Closing at 0.64 - DWinneX
Daily Market Movement: Lexeo Therapeutics Inc (LXEO) Sees a -3.53 Decrease, Closing at 3.55 - DWinneX
Closing Bell Recap: Greenlane Holdings Inc (GNLN) Ends at 0.01, Reflecting a -3.23 Downturn - DWinneX
In the Green: TMD Energy Ltd (TMDE) Closes at 1.58, Up/Down 5.33 from Previous Day - DWinneX
Navigating INTS’s Stock Market Maze: Ups and Downs in 2023 - investchronicle.com
The Business Case For Buying Intensity Therapeutics Inc (NASDAQ: INTS) Stock Now - Stocksregister
Intensity Therapeutics plunges on $2.35M public offering - MSN
US Stock Futures Dip As Oil Prices Continue To Slide - Finimize
Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Community Health (CYH) and Integer Holdings (ITGR) - The Globe and Mail
United States shares higher at close of trade; Dow Jones Industrial Average up 0.05% - Investing.com India
Intensity Therapeutics Inc Azioni (INTS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):